Literature DB >> 17917751

Candidate genes for the progression of malignant gliomas identified by microarray analysis.

Oliver Bozinov1, Sylvia Köhler, Birgit Samans, Ludwig Benes, Dorothea Miller, Markus Ritter, Ulrich Sure, Helmut Bertalanffy.   

Abstract

Malignant astrocytomas of World Health Organization (WHO) grade III or IV have a reduced median survival time, and possible pathways have been described for the progression of anaplastic astrocytomas and glioblastomas, but the molecular basis of malignant astrocytoma progression is still poorly understood. Microarray analysis provides the chance to accelerate studies by comparison of the expression of thousands of genes in these tumours and consequently identify targeting genes. We compared the transcriptional profile of 4,608 genes in tumours of 15 patients including 6 anaplastic astrocytomas (WHO grade III) and 9 glioblastomas (WHO grade IV) using microarray analysis. The microarray data were corroborated by real-time reverse transcription-polymerase chain reaction analysis of two selected genes. We identified 166 gene alterations with a fold change of 2 and higher whose mRNA levels differed (absolute value of the t statistic of 1.96) between the two malignant glioma groups. Further analyses confirmed same transcription directions for Olig2 and IL-13Ralpha2 in anaplastic astrocytomas as compared to glioblastomas. Microarray analyses with a close binary question reveal numerous interesting candidate genes, which need further histochemical testing after selection for confirmation. IL-13Ralpha2 and Olig2 have been identified and confirmed to be interesting candidate genes whose differential expression likely plays a role in malignant progression of astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917751     DOI: 10.1007/s10143-007-0107-3

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  38 in total

Review 1.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.

Authors:  A Giulietti; L Overbergh; D Valckx; B Decallonne; R Bouillon; C Mathieu
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Gene expression profiling of gliomas strongly predicts survival.

Authors:  William A Freije; F Edmundo Castro-Vargas; Zixing Fang; Steve Horvath; Timothy Cloughesy; Linda M Liau; Paul S Mischel; Stanley F Nelson
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

3.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.

Authors:  Dominique B Hoelzinger; Luigi Mariani; Joachim Weis; Tanja Woyke; Theresa J Berens; Wendy S McDonough; Andrew Sloan; Stephen W Coons; Michael E Berens
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

4.  The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.

Authors:  K Kawakami; J Taguchi; T Murata; R K Puri
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen.

Authors:  W Debinski; D M Gibo
Journal:  Mol Med       Date:  2000-05       Impact factor: 6.354

6.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

Authors:  Frederick F Lang; Janet M Bruner; Gregory N Fuller; Kenneth Aldape; Michael D Prados; Susan Chang; Mitchel S Berger; Michael W McDermott; Sandeep M Kunwar; Larry R Junck; William Chandler; James A Zwiebel; Richard S Kaplan; W K Alfred Yung
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

7.  The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.

Authors:  Keith L Ligon; John A Alberta; Alvin T Kho; Jennifer Weiss; Mary R Kwaan; Catherine L Nutt; David N Louis; Charles D Stiles; David H Rowitch
Journal:  J Neuropathol Exp Neurol       Date:  2004-05       Impact factor: 3.685

8.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

Authors:  Arnab Chakravarti; Gary Zhai; Yoshiyuki Suzuki; Sormeh Sarkesh; Peter M Black; Alona Muzikansky; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

9.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction.

Authors:  Jörg van den Boom; Marietta Wolter; Rork Kuick; David E Misek; Andrew S Youkilis; Daniel S Wechsler; Clemens Sommer; Guido Reifenberger; Samir M Hanash
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  10 in total

1.  Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.

Authors:  Basavaraj Vastrad; Chanabasayya Vastrad; Ashok Godavarthi; Raghu Chandrashekar
Journal:  Med Oncol       Date:  2017-09-26       Impact factor: 3.064

2.  OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.

Authors:  Dan Wu; Xufang Yang; Huiming Peng; Dongmin Guo; Weiling Zhao; Chen Zhao; Xiaobo Zhou
Journal:  Carcinogenesis       Date:  2017-09-01       Impact factor: 4.944

Review 3.  Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment.

Authors:  Stephen H Settle; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

4.  Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.

Authors:  Magdalena Ewa Tyburczy; Katarzyna Kotulska; Piotr Pokarowski; Jakub Mieczkowski; Joanna Kucharska; Wieslawa Grajkowska; Maciej Roszkowski; Sergiusz Jozwiak; Bozena Kaminska
Journal:  Am J Pathol       Date:  2010-02-04       Impact factor: 4.307

5.  A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients.

Authors:  Wei Wu; Yichang Wang; Jianyang Xiang; Xiaodong Li; Alafate Wahafu; Xiao Yu; Xiaobin Bai; Ge Yan; Chunbao Wang; Ning Wang; Changwang Du; Wanfu Xie; Maode Wang; Jia Wang
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

6.  Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.

Authors:  Jonathan M Dreyfuss; Mark D Johnson; Peter J Park
Journal:  Mol Cancer       Date:  2009-09-04       Impact factor: 27.401

7.  BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors.

Authors:  Min Wang; Hehuang Xie; Wendy Stellpflug; Veena Rajaram; Maria de Fatima Bonaldo; Stewart Goldman; Tadanori Tomita; Marcelo Bento Soares
Journal:  Neuroinformatics       Date:  2011-03

8.  A double helical motif in OCIAD2 is essential for its localization, interactions and STAT3 activation.

Authors:  Saloni Sinha; Venkata Anudeep Bheemsetty; Maneesha S Inamdar
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

9.  Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR.

Authors:  Valeria Valente; Silvia A Teixeira; Luciano Neder; Oswaldo K Okamoto; Sueli M Oba-Shinjo; Suely K N Marie; Carlos A Scrideli; Maria L Paçó-Larson; Carlos G Carlotti
Journal:  BMC Mol Biol       Date:  2009-03-03       Impact factor: 2.946

10.  A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma.

Authors:  Soumya Alige Mahabala Rao; Sujaya Srinivasan; Irene Rosita Pia Patric; Alangar Sathyaranjandas Hegde; Bangalore Ashwathnarayanara Chandramouli; Arivazhagan Arimappamagan; Vani Santosh; Paturu Kondaiah; Manchanahalli R Sathyanarayana Rao; Kumaravel Somasundaram
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.